Cyclacel Pharmaceuticals ... (CYCC)
NASDAQ: CYCC
· Real-Time Price · USD
7.85
-1.04 (-11.70%)
At close: Aug 15, 2025, 3:59 PM
8.05
2.55%
After-hours: Aug 15, 2025, 06:40 PM EDT
Cyclacel Pharmaceuticals Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -5.01M | -8.27M | -11.21M | -13.43M | -17.51M | -19.7M | -22.55M | -24.7M | -23.77M | -22.89M | -21.2M | -19.07M | -18.96M | -19.52M | -18.89M | -16.4M | -13.66M | -10.7M |
Depreciation & Amortization | 2K | 4K | 6K | 13K | 19K | 25K | 31K | 31K | 31K | 31K | 32K | 31K | 34K | 43K | 43K | 40K | 36K | 24K |
Stock-Based Compensation | 201.67K | 390.67K | 592K | 821K | 1.1M | 1.27M | 1.47M | 1.54M | 1.54M | 1.53M | 1.51M | 1.42M | 1.35M | 1.28M | 1.16M | 994K | 787K | 594K |
Other Working Capital | 1.93M | 3.11M | 4.47M | 4.48M | 4.62M | 7.97M | 4.71M | 2.41M | 471K | -852K | -3.74M | -4.06M | -4.32M | -7.39M | -3.89M | -1.77M | 209K | 365K |
Other Non-Cash Items | 1.59M | 1.57M | -37K | 590K | 549K | 551K | 541K | 16.55M | 17.43M | 18.71M | 18.72M | 2.09M | 1.25M | -15K | n/a | n/a | n/a | -59K |
Deferred Income Tax | n/a | n/a | n/a | -641K | -610K | -610K | -610K | -16.6M | -17.47M | -18.73M | -18.72M | -2.09M | -1.25M | 15K | n/a | n/a | n/a | n/a |
Change in Working Capital | -4.45M | -4.45M | 2.66M | 2.1M | 4.93M | 8.72M | 5.01M | 5.82M | 1.94M | 449K | -1.17M | -2.59M | -1.87M | -3.56M | -853K | 220K | 1.78M | 1.45M |
Operating Cash Flow | -7.67M | -10.75M | -7.99M | -10.54M | -11.51M | -9.73M | -16.11M | -17.37M | -20.3M | -20.91M | -20.83M | -20.21M | -19.45M | -21.75M | -18.54M | -15.14M | -11.06M | -8.69M |
Capital Expenditures | n/a | n/a | n/a | n/a | n/a | n/a | -6K | -6K | -6.01K | -9.01K | -7.01K | -9.01K | -18K | 47K | -27K | -67K | -108K | -170K |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | n/a | -4.21M | n/a | n/a | n/a | 4.21M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Investing Cash Flow | n/a | n/a | n/a | -4.21M | n/a | n/a | -6K | 4.21M | -6.01K | -9.01K | -7.01K | -9.01K | -18K | 47K | -27K | -67K | -108K | -170K |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | -41 | n/a | n/a | -50K | -100K | -151K | -201K | -201K | -201K | -201K | -201K | -201K | -201K | -201K | -201K | -201K | -201K | -201K |
Other Financial Acitivies | 1.61M | 1.61M | 1.61M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Financial Cash Flow | 5.26M | 11.55M | 7.82M | 7.21M | 7.16M | 819K | 848K | -109K | 1.47M | 3M | 3M | 3.84M | 5.21M | 3.69M | 21.74M | 32.2M | 29.24M | 47.55M |
Net Cash Flow | -2.55M | 652K | -241K | -2.96M | -4.16M | -8.64M | -14.97M | -17.76M | -18.91M | -18.2M | -18.21M | -16.51M | -14.56M | -18.14M | 3.15M | 17.09M | 18.3M | 38.85M |
Free Cash Flow | -4.43M | -7.51M | -7.99M | -10.54M | -11.51M | -9.73M | -16.12M | -17.38M | -20.31M | -20.92M | -20.83M | -20.22M | -19.47M | -21.7M | -18.57M | -15.21M | -11.17M | -8.86M |